News
Zacks Investment Research on MSN8d
AZN Gets CHMP Nod for Imfinzi in Muscle-Invasive Bladder CancerAstraZeneca AZN announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) rendered ...
AstraZeneca (AZN) stock in focus as its antibody drug Imfinzi gains EU panel support for treating muscle-invasive bladder ...
Sales of AstraZeneca’s key medicines, mainly cancer drugs — Lynparza, Tagrisso and Imfinzi — and diabetes ... inhibitors class of drugs and some label restrictions for use in second-line ...
AstraZeneca's human monoclonal antibody Imfinzi (durvalumab), when combined ... The multi-centre, open-label, global study is assessing the combo in 1,018 BCG-naïve NMIBC subjects after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback